Repros Therapeutics Inc (NASDAQ:RPRX) saw a significant decrease in short interest in the month of January. As of January 31st, there was short interest totalling 852,002 shares, a decrease of 34.8% from the January 12th total of 1,307,720 shares. Based on an average trading volume of 393,922 shares, the days-to-cover ratio is presently 2.2 days. Currently, 2.2% of the shares of the company are sold short.
Shares of Repros Therapeutics (NASDAQ:RPRX) opened at $0.67 on Monday. Repros Therapeutics has a 12-month low of $0.26 and a 12-month high of $1.33. The firm has a market capitalization of $26.50, a P/E ratio of -1.34 and a beta of 0.45.
Repros Therapeutics (NASDAQ:RPRX) last posted its quarterly earnings data on Monday, November 13th. The biotechnology company reported ($0.04) earnings per share for the quarter, beating the consensus estimate of ($0.28) by $0.24. Repros Therapeutics had a negative return on equity of 894.22% and a negative net margin of 4,242.73%. The company had revenue of $0.30 million during the quarter.
Separately, S&P Equity Research reduced their price objective on Repros Therapeutics from $0.49 to $0.39 in a research report on Monday, November 20th.
WARNING: “Short Interest in Repros Therapeutics Inc (RPRX) Declines By 34.8%” was first posted by American Banking News and is owned by of American Banking News. If you are accessing this piece on another domain, it was illegally stolen and reposted in violation of US & international copyright and trademark laws. The legal version of this piece can be read at https://www.americanbankingnews.com/2018/02/12/short-interest-in-repros-therapeutics-inc-rprx-declines-by-34-8.html.
About Repros Therapeutics
Repros Therapeutics, Inc is a biopharmaceutical company focused on the development of new drugs to treat hormonal and reproductive system disorders. The Company’s product candidates include enclomiphene, which is a single isomer of clomiphene citrate, an orally active small molecule compound, and Proellex, which is an orally administered selective blocker of the progesterone receptor in women, for the treatment of uterine fibroids and endometriosis.
Receive News & Ratings for Repros Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repros Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.